From the circumsporozoite protein to the RTS, S/AS candidate vaccine.
about
European Vaccine Initiative: lessons from developing malaria vaccinesA review of malaria vaccine clinical projects based on the WHO rainbow tableUse of massively parallel pyrosequencing to evaluate the diversity of and selection on Plasmodium falciparum csp T-cell epitopes in Lilongwe, MalawiVaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infectionSelf-assembling protein nanoparticles in the design of vaccinesIn vivo CD8+ T cell dynamics in the liver of Plasmodium yoelii immunized and infected miceIdentification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite ProteinInhibitor of cysteine proteases is critical for motility and infectivity of Plasmodium sporozoitesIdentification of targets of CD8⁺ T cell responses to malaria liver stages by genome-wide epitope profilingSafety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian ChildrenInactivation of a Plasmodium apicoplast protein attenuates formation of liver merozoitesA bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugates.Imaging liver-stage malaria parasites.Subviral particle as vaccine and vaccine platform.Prospects for malaria elimination in non-Amazonian regions of Latin America.Toward a surrogate marker of malaria exposure: modeling longitudinal antibody measurements under outbreak conditionsEfficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody.IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.Plasmodium immunomics.A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malariaFractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.Vaccines against malaria-still a long way to go.Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adultsMalaria Vaccine Development: Are Bacterial Flagellin Fusion Proteins the Bridge between Mouse and Humans?Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens.Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigensComparative decline in funding of European Commission malaria vaccine projects: what next for the European scientists working in this field?Antibodies to Plasmodium circumsporozoite protein (CSP) inhibit sporozoite's cell traversal activityGenetic diversity and population structure of genes encoding vaccine candidate antigens of Plasmodium vivax.Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.PFE0565w, a Plasmodium falciparum protein expressed in salivary gland sporozoitesRecent advances in recombinant protein-based malaria vaccines.Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in miImmunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.Identification of non-CSP antigens bearing CD8 epitopes in mice immunized with irradiated sporozoites.Analysis of the dose-dependent stage-specific in vitro efficacy of a multi-stage malaria vaccine candidate cocktail.Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adultsVaccines for the future: learning from human immunologyA monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum.
P2860
Q21032652-694C7F0F-ADCD-4264-B83F-641A9857CF8AQ21034112-6A165900-9A1F-461A-B75A-0AF5558038D3Q24617275-AE64FD41-16A8-48B7-97EF-797F2A9C0C34Q24628167-806507E8-0425-4B76-8AC4-D89B37026E8BQ26767097-9E11DC49-F6E1-407F-810E-240E21BC469DQ27310073-05971048-7EE1-47FC-A7B8-24330495FF06Q27973488-B50FC1A7-A5A2-4C3F-8EBC-208F19731B2CQ27974412-CE3A987D-6D2F-44C2-AE85-CBBDCAF6DA8DQ28704543-64A748A8-95B5-4EF4-B813-7E08212CAAABQ28744573-3B5E0DD2-55E6-45A4-83AC-81FAACD8B007Q30043892-D6E321DB-72D2-42E2-8381-A80311A2F3C6Q33524699-12952775-8E90-435C-ABD4-6A0CD523E8D3Q33533866-76BF8D44-CAA3-481E-87C5-AF5776B0732CQ33812653-BFBFA492-7D98-4B54-B559-96B214B97346Q33969129-93E295A6-3E57-46E7-A8CB-7BAD4DA27FF1Q33982957-03D90E8A-4CDE-4DB7-81AD-C243A6B8FB72Q34043843-5398648D-6A89-4DD9-A512-182CD6C8EAC1Q34241973-9B7CC88D-1A90-4731-97A2-3E3C24FC6460Q34400813-4BFDE390-6167-41EF-9C4E-A131749AEC0FQ34419934-45467C13-7A72-421F-ABA1-F6730C864494Q34469817-E0742AB7-9E08-4E4E-957F-ACC04B66B788Q34530710-5C353FC7-1826-42D7-81E7-82B60F9B15C6Q34556687-E099B5D9-9438-44BB-9BEE-9B31E39E37CEQ34634002-546A31B4-30D9-4E1F-A00F-B5B2E90DA381Q34983659-667D0811-0004-480D-B6D8-9F113BCBE2CFQ35264640-D956FE6A-5E16-49A3-A775-B6033FDB6EF7Q35330733-09BD3FA6-C724-4208-A99A-CA94A89D8CDCQ35390050-343C9B31-51A6-4CBA-9AE6-EA3B5E9FC357Q35846177-6C13ECD5-9FC1-41B5-A11C-3EA29D613ABCQ35898837-2E4CC721-3537-45C9-A60A-762BA59C2A2FQ35937418-2A306AF7-70BE-4EDB-87DD-38270677E621Q36005905-F881E6CE-A0CA-4A71-9A1A-B8B4014A8528Q36394182-124A139C-306B-4A8C-AA35-95EBDC547669Q36646698-749DFFCB-20A1-4BD0-9D3B-E201A067A3C9Q36686924-6F6BB330-AC15-433A-B2CA-A8084F2F3E88Q36702125-70D5B6C5-824A-4DC5-8DB8-C8425A499D11Q36906995-25DD8498-4D8E-49D6-AB43-68AF5C384CC2Q36978351-C95E6879-11C6-4469-A05A-296AB7725565Q37274689-05479E99-666D-4BC7-8902-36D8C3753AA5Q37402867-82E73445-06DE-41E2-A6D5-9E536735D023
P2860
From the circumsporozoite protein to the RTS, S/AS candidate vaccine.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
From the circumsporozoite protein to the RTS, S/AS candidate vaccine.
@en
From the circumsporozoite protein to the RTS, S/AS candidate vaccine.
@nl
type
label
From the circumsporozoite protein to the RTS, S/AS candidate vaccine.
@en
From the circumsporozoite protein to the RTS, S/AS candidate vaccine.
@nl
prefLabel
From the circumsporozoite protein to the RTS, S/AS candidate vaccine.
@en
From the circumsporozoite protein to the RTS, S/AS candidate vaccine.
@nl
P2093
P356
P1433
P1476
From the circumsporozoite protein to the RTS, S/AS candidate vaccine.
@en
P2093
Amanda Leach
Johan Vekemans
Victor Nussenzweig
P356
10.4161/HV.6.1.9677
P577
2010-01-30T00:00:00Z